Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Editas Medicine, Inc.

Contributing Author

Recent Articles by Editas Medicine, Inc.

Sep-01
Editas Medicine to Participate in Upcoming Investor Conferences EDIT GlobeNewswire
Aug-05
Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT EDIT +5.45% GlobeNewswire
Aug-04
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. EDIT GlobeNewswire
May-28
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference EDIT GlobeNewswire
May-26
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering EDIT +11.59% GlobeNewswire
May-26
Editas Medicine Announces Proposed Public Offering EDIT +11.59% GlobeNewswire
May-26
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress EDIT +11.59% GlobeNewswire
May-14
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting EDIT GlobeNewswire
May-05
Editas Medicine Announces First Quarter 2026 Results and Business Updates EDIT GlobeNewswire
Apr-27
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences EDIT EDIT +5.88% GlobeNewswire
Mar-27
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference EDIT GlobeNewswire
Mar-09
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates EDIT +16.00% GlobeNewswire
Feb-23
Editas Medicine to Participate in Upcoming Investor Conferences EDIT +5.59% GlobeNewswire
Nov-10
Editas Medicine Announces Third Quarter 2025 Results and Business Updates EDIT GlobeNewswire
Nov-03
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 EDIT GlobeNewswire
Oct-09
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress EDIT GlobeNewswire
Oct-06
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences EDIT GlobeNewswire
Sep-02
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate EDIT GlobeNewswire
Aug-28
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate EDIT GlobeNewswire
Aug-27
Editas Medicine to Participate in Upcoming Investor Conferences EDIT GlobeNewswire
Aug-12
Editas Medicine Announces Second Quarter 2025 Results and Business Updates EDIT EDIT +34.50% GlobeNewswire
Jun-12
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June EDIT +7.39% GlobeNewswire
May-14
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June EDIT -8.00% GlobeNewswire
May-14
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting EDIT -8.00% GlobeNewswire
May-13
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting EDIT GlobeNewswire
May-12
Editas Medicine Announces First Quarter 2025 Results and Business Updates EDIT +6.21% GlobeNewswire
May-12
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board EDIT +6.21% GlobeNewswire
May-05
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May EDIT -6.10% EDIT -13.64% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)